Halyna Pylypenko

3.8k total citations · 1 hit paper
29 papers, 1.3k citations indexed

About

Halyna Pylypenko is a scholar working on Genetics, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Halyna Pylypenko has authored 29 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 14 papers in Oncology and 13 papers in Pathology and Forensic Medicine. Recurrent topics in Halyna Pylypenko's work include Lymphoma Diagnosis and Treatment (13 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Halyna Pylypenko is often cited by papers focused on Lymphoma Diagnosis and Treatment (13 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Halyna Pylypenko collaborates with scholars based in Czechia, Poland and France. Halyna Pylypenko's co-authors include Sebastian Grosicki, Helgi van de Velde, Tadeusz Robak, Xavier Leleu, Philippe Moreau, William Deraedt, Bertrand Arnulf, James Cavet, Dixie‐Lee Esseltine and Jean‐Luc Harousseau and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Halyna Pylypenko

29 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

2011 661 citations Philippe Moreau, Halyna Pylypenko et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Halyna Pylypenko Czechia	11	747	736	672	389	341	29	1.3k
Leonard T. Heffner United States	21	996 1.3×	856 1.2×	784 1.2×	561 1.4×	464 1.4×	86	1.8k
Dixie‐Lee Esseltine United States	11	1.1k 1.5×	1.2k 1.6×	817 1.2×	285 0.7×	190 0.6×	12	1.8k
Zvenyslava Masliak Poland	6	1.6k 2.2×	1.3k 1.7×	997 1.5×	300 0.8×	134 0.4×	9	1.9k
Ira Gupta United States	23	870 1.2×	639 0.9×	753 1.1×	719 1.8×	717 2.1×	76	2.0k
Kena C. Miller United States	18	696 0.9×	615 0.8×	468 0.7×	636 1.6×	506 1.5×	69	1.4k
Huaibao Feng United States	13	1.1k 1.5×	859 1.2×	796 1.2×	229 0.6×	110 0.3×	30	1.4k
Anuj Mahindra United States	17	918 1.2×	703 1.0×	477 0.7×	227 0.6×	95 0.3×	56	1.2k
Joanne Lager United States	17	296 0.4×	563 0.8×	439 0.7×	389 1.0×	215 0.6×	37	1.2k
Andrew Cakana United States	20	1.5k 1.9×	1.4k 1.9×	948 1.4×	299 0.8×	62 0.2×	48	1.9k
Karthik Ramasamy United Kingdom	18	918 1.2×	788 1.1×	614 0.9×	147 0.4×	97 0.3×	142	1.2k

Countries citing papers authored by Halyna Pylypenko

Since Specialization

Citations

This map shows the geographic impact of Halyna Pylypenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Halyna Pylypenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Halyna Pylypenko more than expected).

Fields of papers citing papers by Halyna Pylypenko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Halyna Pylypenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Halyna Pylypenko. The network helps show where Halyna Pylypenko may publish in the future.

Co-authorship network of co-authors of Halyna Pylypenko

This figure shows the co-authorship network connecting the top 25 collaborators of Halyna Pylypenko. A scholar is included among the top collaborators of Halyna Pylypenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Halyna Pylypenko. Halyna Pylypenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Levy, Moshe, Marek Trněný, Wojciech Jurczak, et al.. (2021). SAFETY AND EFFICACY OF CD37‐TARGETING NARATUXIMAB EMTANSINE PLUS RITUXIMAB IN DIFFUSE LARGE B‐CELL LYMPHOMA AND OTHER NON‐HODGKIN’S B‐CELL LYMPHOMAS – A PHASE 2 STUDY. Hematological Oncology. 39(S2). 3 indexed citations

Façon, Thierry, Holger W. Auner, Maria Gavriatopoulou, et al.. (2021). Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.. Journal of Clinical Oncology. 39(15_suppl). 8019–8019. 1 indexed citations

Levy, Moshe, Deepa Jagadeesh, Marek Trněný, et al.. (2021). Safety and Efficacy of CD37-Targeting Naratuximab Emtansine PLUS Rituximab in Diffuse Large B-Cell Lymphoma and Other NON-Hodgkin'S B-Cell Lymphomas - a Phase 2 Study. Blood. 138(Supplement 1). 526–526. 11 indexed citations

Leleu, Xavier, María‐Victoria Mateos, Sundar Jagannath, et al.. (2021). Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.. Journal of Clinical Oncology. 39(15_suppl). 8024–8024. 4 indexed citations

Dimopoulos, Meletios Α., Sosana Delimpasi, Maryana Simonova, et al.. (2020). Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.. Journal of Clinical Oncology. 38(15_suppl). 8501–8501. 22 indexed citations

Gisslinger, Heinz, Christoph Klade, Pencho Georgiev, et al.. (2020). Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension. Blood. 136(Supplement 1). 33–33. 10 indexed citations

Gisslinger, Heinz, Christoph Klade, Pencho Georgiev, et al.. (2019). Ropeginterferon Alfa-2b versus Standard Therapy for Polycythaemia Vera; a Randomised, Controlled, Phase III Trial. SSRN Electronic Journal. 5 indexed citations

Gisslinger, Heinz, Christoph Klade, Pencho Georgiev, et al.. (2018). Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT. Blood. 132(Supplement 1). 579–579. 14 indexed citations

Verhoef, Gregor, Tadeusz Robak, Huiqiang Huang, et al.. (2017). Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study. Haematologica. 102(5). 895–902. 3 indexed citations

10.

Robak, Tadeusz, Huiqiang Huang, Jie Jin, et al.. (2017). Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study. Leukemia & lymphoma. 60(1). 172–179. 9 indexed citations

11.

Fraser, Graeme, Paula Cramer, Fatih Demırkan, et al.. (2016). IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY. Haematologica. 101. 150–151. 4 indexed citations

12.

Fraser, Graeme, Paula Cramer, Fatih Demırkan, et al.. (2016). Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study.. Journal of Clinical Oncology. 34(15_suppl). 7525–7525. 8 indexed citations

13.

Kipps, Thomas J., Herbert Eradat, Sebastian Grosicki, et al.. (2015). A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leukemia & lymphoma. 56(10). 2826–2833. 151 indexed citations

14.

Robak, Tadeusz, Huiqiang Huang, Jie Jin, et al.. (2015). Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma. New England Journal of Medicine. 372(10). 944–953. 261 indexed citations

15.

Chanan‐Khan, Asher, Paula Cramer, Fatih Demırkan, et al.. (2015). Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.. Journal of Clinical Oncology. 33(15_suppl). LBA7005–LBA7005. 3 indexed citations

16.

Robak, Tadeusz, Huiqiang Huang, Jie Jin, et al.. (2014). Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study. Blood. 124(21). 4412–4412. 3 indexed citations

17.

Arnulf, Bertrand, Halyna Pylypenko, Sebastian Grosicki, et al.. (2012). Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 97(12). 1925–1928. 87 indexed citations

18.

Eradat, Herbert, Sebastian Grosicki, Walter Cosolo, et al.. (2012). Preliminary Results of a Phase II Open-Label, Randomized Study of the BH3 Mimetic Protein Navitoclax (ABT-263) with or without Rituximab for Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia. Blood. 120(21). 190–190. 7 indexed citations

19.

Moreau, Philippe, Halyna Pylypenko, Sebastian Grosicki, et al.. (2011). Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. The Lancet Oncology. 12(5). 431–440. 661 indexed citations breakdown →

20.

Moreau, Philippe, Halyna Pylypenko, Sebastian Grosicki, et al.. (2010). A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma. Blood. 116(21). 312–312. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact